The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Updates in mesothelioma and small cell lung cancer at WCLC 2026
Dean Fennell, FRCP, PhD, FRSB, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK, provides his highlights from the 2026 World Conference on Lung Cancer congress, including results of the B7-H3-directed antibody-drug conjugate (ADC) in relapsed small cell lung cancer (SCLC). Dr Fennell also mentions presenting new data on a trial in progress for a PRMT5 inhibitor targeting MTAP deleted mesotheliomas, aiming to exploit synthetic lethality in this aggressive disease. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, you know, I think I’ve just heard it, the B7H3 ADC in relapsed small cell. The results have been very exciting, and that was one of my highlights, I think. Looking forward to that. I should also mention we’re just presenting some data. It’s been a poster format as a trial in progress. We have a new, quite therapy for mesothelioma targeting MTAP deleted mesotheliomas...
Well, you know, I think I’ve just heard it, the B7H3 ADC in relapsed small cell. The results have been very exciting, and that was one of my highlights, I think. Looking forward to that. I should also mention we’re just presenting some data. It’s been a poster format as a trial in progress. We have a new, quite therapy for mesothelioma targeting MTAP deleted mesotheliomas. This is using a PRMT5 inhibitor and so we’re looking to see whether through synthetic lethality we can actively target this disease, quite an aggressive form of mesothelioma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
